520
Participants
Start Date
June 30, 2016
Primary Completion Date
March 31, 2017
Study Completion Date
March 31, 2017
KPI-121 1% Ophthalmic Suspension dosed BID
Vehicle of KPI-121 Ophthalmic Suspension dosed BID
Eye Care Specialists, Kingston
Duke University Eye Center, Durham
Carolina Cataract & Laser Center, Ladson
Carolina Eyecare Physicians, LLC, Mt. Pleasant
Levenson Eye Associates, Jacksonville
International Research Center, Tampa
Shettle Eye Research, Inc, Largo
Eye Associates of Fort Myers, Fort Myers
The Eye Care Institute, Louisville
Apex Eye, Cincinnati
Great Lakes Eye Care, Saint Joseph
Minnesota Eye Consultants, PA, Bloomington
Jacksoneye, S. C., Lake Villa
Chicago Cornea Consultants, Ltd., Hoffman Estates
Comprehensive Eye Care, Ltd. / Vision Research Institute, LLC, Washington
Houston Eye Associates, Houston
Kozlovsky Delay & Winter Eye Consultants, LLC Corona Research, San Antonio
Texan Eye, PA / Keystone Research, Ltd, Austin
The Cataract & Glaucoma Center, El Paso
Eye Center of Northern Colorado, PC, Fort Collins
Cornea and Cataract Consultants of CA, Phoenix
Arizona Eye Center, Chandler
Abrams Eye Institute, Las Vegas
United Medical Research Institute, Inglewood
Sall Research Medical Center, Artesia
Lugene Eye Institute, Glendale
Pendleton Eye Center, Oceanside
Arch Health Partners, Poway
Inland Eye Specialists, Hemet
LoBue Laser and Eye Medical Center, Murrieta
Orange County Ophthalmology, Garden Grove
North Bay Eye Associates, Inc., Petaluma
Martel Eye Medical Group, Rancho Cordova
Shasta Eye Medical Group, Inc, Redding
Roseburg Research Associates, LLC, Roseburg
Lead Sponsor
Kala Pharmaceuticals, Inc.
INDUSTRY